PLX Protalix BioTherapeutics, Inc. Stock Quote

PLX [AMEX]

Index	-	P/E	-	EPS (ttm)	-0.22	Insider Own	27.50%	Shs Outstand	45.38M	Perf Week	17.87%
Market Cap	281.37M	Forward P/E	6.89	EPS next Y	0.90	Insider Trans	0.00%	Shs Float	29.81M	Perf Month	21.81%
Income	-	PEG	-	EPS next Q	-0.02	Inst Own	10.64%	Short Float	5.34%	Perf Quarter	56.96%
Sales	62.90M	P/S	4.47	EPS this Y	104.50%	Inst Trans	-	Short Ratio	1.65	Perf Half Y	66.67%
Book/sh	-0.78	P/B	-	EPS next Y	8900.00%	ROA	-	Target Price	-	Perf Year	79.71%
Cash/sh	-	P/C	-	EPS next 5Y	25.00%	ROE	-	52W Range	2.81 - 7.02	Perf YTD	70.80%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-15.81%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	110.32%	ATR	0.33
Employees	207	Current Ratio	-	Sales Q/Q	9.80%	Oper. Margin	-	RSI (14)	63.53	Volatility	7.62% 6.55%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	36.40%	Profit Margin	-	Rel Volume	1.79	Prev Close	6.20
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 30 BMO	Payout	-	Avg Volume	964.91K	Price	5.91
Recom	2.00	SMA20	14.28%	SMA50	17.09%	SMA200	46.93%	Volume	1,253,127	Change	-4.68%

Jun-08-20

Reiterated

H.C. Wainwright

Buy

$3 → $11

Apr-17-17

Reiterated

Rodman & Renshaw

Buy

$4 → $5

Apr-04-16

Initiated

Rodman & Renshaw

Buy

$3.50

Apr-23-15

Upgrade

Jefferies

Hold → Buy

$2 → $2.60

Nov-12-14

Reiterated

R. F. Lafferty

Buy

$8 → $5

Jan-24-14

Initiated

R. F. Lafferty

Buy

May-02-12

Reiterated

Oppenheimer

Outperform

$9 → $11

May-02-12

Downgrade

Canaccord Genuity

Buy → Hold

$8 → $8

Apr-30-12

Downgrade

Auriga

Buy → Hold

$8 → $8

Oct-13-11

Initiated

Morgan Joseph

Hold

Mar-17-11

Downgrade

WBB Securities

Strong Buy → Buy

$10

Nov-09-10

Reiterated

Oppenheimer

Outperform

$10 → $12

Oct-14-10

Reiterated

UBS

Buy

$9 → $10.75

Dec-02-09

Reiterated

Hapoalim

Outperform

$10 → $12

Sep-22-09

Initiated

Canaccord Adams

Buy

Sep-02-09

Initiated

Hapoalim

Outperform

$10

Dec-01-08

Reiterated

Oppenheimer

Outperform

$6 → $4

Mar-11-08

Initiated

UBS

Buy

Nov-20-07

Initiated

CIBC Wrld Mkts

Sector Outperform

Apr-07-21 05:15AM	PLX: Target Action Date Four Weeks Away Zacks Small Cap Research
Mar-30-21 06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results PR Newswire
06:30AM	Protalix Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-22-21 06:50AM	Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021 PR Newswire +6.67%
Mar-04-21 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference PR Newswire -11.21%
Feb-24-21 08:03AM	PLX: A Busy Month Zacks Small Cap Research +11.33%
Feb-23-21 08:04AM	Protalix's PRX102 Monthly Treatment Shows Benefit In Fabry Disease Benzinga
07:25AM	The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga
06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease PR Newswire
Feb-22-21 03:20AM	Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Is About To Turn The Corner Simply Wall St.
Feb-18-21 08:02AM	Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds PR Newswire
Feb-12-21 05:54AM	Protalix BioTherapeutics Raises $35M Via Equity At 21% Discount Benzinga -15.37%
Feb-11-21 09:16PM	Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock PR Newswire
04:35PM	Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock PR Newswire
07:47AM	Protalix BioTherapeutics Perks Up On Alidornase Alfa Licensing Pact In Respiratory Conditions Benzinga
07:26AM	The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts Benzinga
06:50AM	Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery PR Newswire
Feb-10-21 07:01AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium 2021 PR Newswire -10.85%
Feb-01-21 06:50AM	Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium 2021 PR Newswire
Jan-04-21 06:50AM	Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January PR Newswire
04:25AM	PLX: Final Results for BRIDGE and A Letter to Shareholders Zacks Small Cap Research
Dec-30-20 06:50AM	Protalix BioTherapeutics Issues 2020 Letter to Shareholders PR Newswire
06:00AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease PR Newswire
Dec-21-20 06:40AM	Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year? Simply Wall St.
Dec-15-20 07:15AM	PLX: FDA Approval To Start New Chapter Zacks Small Cap Research +5.90%
Nov-30-20 03:38PM	Is Protalix BioTherapeutics Inc. (PLX) A Good Stock To Buy Now? Insider Monkey
Nov-27-20 06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease PR Newswire -5.97%
Nov-05-20 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference PR Newswire
Oct-29-20 01:33PM	Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30 PR Newswire -5.63%
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update PR Newswire
06:30AM	Protalix Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-26-20 06:50AM	Protalix BioTherapeutics to Participate in Virtual Investor KOL Roundtable PR Newswire
Oct-22-20 06:50AM	Protalix BioTherapeutics to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on October 29, 2020 PR Newswire
Oct-20-20 12:13PM	Do Institutions Own Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares? Simply Wall St.
Oct-02-20 08:00AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease PR Newswire
Sep-08-20 06:55AM	Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards PR Newswire
06:45AM	Protalix BioTherapeutics to Present in the H.C. Wainwright 22nd Annual Global Investment Virtual Conference PR Newswire
Aug-24-20 06:50AM	Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the Proposed Treatment of Fabry Disease PR Newswire
Aug-20-20 03:44PM	Loss-Making Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Expected To Breakeven Simply Wall St.
Aug-11-20 06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review PR Newswire
Aug-10-20 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update PR Newswire
Aug-06-20 01:02PM	Protalix BioTherapeutics to Present at the BTIG Virtual Biotechnology Conference 2020 PR Newswire
Aug-03-20 09:13AM	Protalix BioTherapeutics to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on August 10, 2020 PR Newswire
Jul-23-20 02:29PM	Protalix BioTherapeutics Enters into Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Diseases PR Newswire
Jul-22-20 07:28PM	Edited Transcript of PLX.A earnings conference call or presentation 1-Jun-20 12:30pm GMT Thomson Reuters StreetEvents
Jun-18-20 12:20PM	Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares? Simply Wall St. +9.57%
Jun-08-20 05:00PM	Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development PR Newswire +7.24%
Jun-03-20 08:46PM	Edited Transcript of PLX earnings conference call or presentation 12-Mar-20 12:30pm GMT Thomson Reuters StreetEvents
Jun-01-20 06:50AM	Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update PR Newswire
06:30AM	Protalix Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-29-20 09:43AM	Protalix Submits BLA for Fabry Disease Candidate PRX-102 Zacks -5.92%
May-28-20 06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease PR Newswire
May-22-20 04:05PM	Protalix BioTherapeutics to Hold First Quarter 2020 Financial Results and Business Update Conference Call on June 1, 2020 PR Newswire
May-11-20 06:50AM	Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease PR Newswire +5.31%
Mar-18-20 12:12PM	Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement PR Newswire
Mar-16-20 06:50AM	Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein PR Newswire -8.30%
Mar-12-20 08:04AM	Protalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results PR Newswire
07:55AM	Protalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease PR Newswire
Mar-05-20 07:00AM	Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020 PR Newswire
Feb-11-20 10:52AM	Protalix BioTherapeutics, Inc.'s (NYSEMKT:PLX) Profit Outlook Simply Wall St.
Feb-10-20 04:05PM	Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium 2020 PR Newswire
Feb-06-20 06:50AM	Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease PR Newswire
Feb-04-20 09:00AM	Protalix BioTherapeutics to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference PR Newswire
Jan-30-20 07:30AM	Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium 2020 PR Newswire
Jan-14-20 05:09PM	Seattle Seahawks' top 10 plays \| 2019 season NFL Highlights -7.87%
Dec-19-19 06:50AM	Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors PR Newswire
Dec-09-19 04:05PM	Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split PR Newswire
Nov-29-19 10:37PM	Hedge Funds Watching Protalix BioTherapeutics Inc. (PLX) From Afar Insider Monkey +8.78%
Nov-27-19 06:50AM	Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX102 Drug Candidate for the Treatment of Fabry Disease PR Newswire +6.76%
12:11AM	Edited Transcript of PLX earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-19-19 09:26AM	Protalix Finalizes Accelerated Approval Pathway for PRX-102 Zacks -7.83%
Nov-18-19 06:50AM	Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States PR Newswire +32.31%
Nov-13-19 11:59AM	Some Protalix BioTherapeutics (NYSEMKT:PLX) Shareholders Have Taken A Painful 90% Share Price Drop Simply Wall St.
Nov-07-19 09:25AM	Protalix (PLX) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update PR Newswire
Oct-31-19 10:34AM	Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks -9.38%
Oct-29-19 07:00AM	Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019 PR Newswire
Oct-17-19 07:40AM	Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease PR Newswire +74.03%
Sep-25-19 06:22PM	Protalix Completes Enrollment in Third Fabry Disease Study Zacks +8.75%
Sep-24-19 07:00AM	Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX102) for the Treatment of Fabry Disease PR Newswire
Sep-02-19 11:40AM	Edited Transcript of PLX earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-30-19 04:15PM	Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American GlobeNewswire
Aug-26-19 03:18PM	Protalix BioTherapeutics, Inc. (NYSEMKT:PLX): Is Breakeven Near? Simply Wall St.
Aug-22-19 08:45AM	Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships GlobeNewswire +6.21%
Aug-13-19 04:05PM	Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics GlobeNewswire
Aug-08-19 07:30AM	Protalix (PLX) Reports Q2 Loss, Tops Revenue Estimates Zacks -37.78%
06:05AM	Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update GlobeNewswire
Aug-01-19 10:32AM	Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-29-19 04:01PM	Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019 GlobeNewswire -6.03%
07:00AM	Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer GlobeNewswire
Jul-11-19 02:16PM	Do Institutions Own Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares? Simply Wall St.
Jun-18-19 10:27AM	Protalix (PLX) Completes Enrollment in Fabry Disease Study Zacks
Jun-17-19 07:00AM	Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease GlobeNewswire
Jun-06-19 07:00AM	Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States GlobeNewswire +35.17%
May-31-19 08:58AM	Why Przetwórstwo Tworzyw Sztucznych Plast-Box S.A.'s (WSE:PLX) High P/E Ratio Isn't Necessarily A Bad Thing Simply Wall St.
May-21-19 07:00AM	Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director GlobeNewswire
May-14-19 12:50AM	Edited Transcript of PLX earnings conference call or presentation 6-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-09-19 01:41AM	Przetwórstwo Tworzyw Sztucznych Plast-Box S.A. (WSE:PLX) Delivered A Weaker ROE Than Its Industry Simply Wall St.
May-06-19 08:15AM	Protalix (PLX) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:09AM	Protalix: 1Q Earnings Snapshot Associated Press

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundacao Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience